A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in
Tractament antiviral de l'hepatitis C crònica
Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España
Sofosbuvir, Velpatasvir, and Voxilaprevir (SOF/VEL/VOX) VOSEVI® Criteria for Use December 2019
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Prior Treartment Failures with Glecaprevir/Pibrentasvir (G/P) in Chronic Hepatitis C Infection
TREATMENT WITH SOF/VEL/VOX IN HIV-HCV COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs
Nuria Cerón (@Nuria_CeronS) / Twitter
Sofosbuvir-Velpatasvir-Voxilaprevir Vosevi - Treatment - Hepatitis C Online
Sofosbuvir/Velpatasvir/Voxilaprevir: A Highly Effective Option for Retreatment of Hepatitis C in Difficult-to-treat Patients - Poonam Mathur, Shyamasundaran Kottilil, Eleanor Wilson, 2019
Sofosbuvir-Velpatasvir-Voxilaprevir Vosevi - Treatment - Hepatitis C Online
Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation - Cardona‐Gonzalez - 2018 - Hepatology Communications - Wiley Online Library
PDF) Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus
SOF/VEL/VOX and Other Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hepatitis C Virus in Patients Receiving Opioid Substitution Therapy: An Analysis. - ppt download
PDF) Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study
Vosevi | Positively Aware
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan,Hepatology International - X-MOL
SOF/VEL/VOX Effective as Retreatment for Non-NS5A DAA Failures - MPR
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®) | SpringerLink
Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3 - ppt download
SciELO - Brasil - Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a
